BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights that the company expanded their long-term care and psychiatry salesforce teams last September, is looking for FY25 guidance on the Q4 earnings call as well as color on the expected return from the salesforce investment in 2025 and beyond.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $185 from $170 at Morgan Stanley
- NBIX Upcoming Earnings Report: What to Expect?
- Neurocrine price target raised to $176 from $162 at UBS
- Neurocrine initiates Phase 3 registrational program for osavampator in MDD
- Closing Bell Movers: Graco down 5% as earnings, guidance miss